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Abstract 
Endocarditis, or heart valve infection, can be caused by a number of pathogens, 
many of which are Gram-positive bacteria. The diagnosis is based on imaging 
techniques such as echocardiography and on blood culture. The implementation of 
fast and accurate species identification methods, such as the matrix-assisted laser 
desorption/ionisation-time of flight mass spectrometry (MALDI-TOF MS) in 
routine use for bacteria found in blood culture, has meant that bacteria previously 
thought to be rare have become increasingly recognised in the clinic. Some of 
these newly recognised bacteria are the aerococci, a genus of bacteria consisting of 
eight identified species, first identified in 1956. Other areas where MALDI-TOF 
MS and other new bacteriological methods have been helpful are the 
differentiation between the groups of NBHS (non-beta-haemolytic streptococci), 
also known as alpha streptococci, and in the identification of other Gram-positive 
cocci such as Abiotrophia, Gemella, and Granulicatella. 
This thesis consists of six different studies on endocarditis and endocarditis-
causing Gram-positive bacteria. The first of these covers Aerococcus urinae. 
Using mass spectrometry, two distinct LPATG-anchored proteins named Asp 1 
and Asp 2 were identified on the surface of the bacterium. The presence of these 
proteins was also confirmed using antibodies generated against recombinantly 
expressed Asp 1 and Asp 2. After sequencing 25 A. urinae genomes, six different 
variants of asp genes, named asp1-6, were found. All sequenced isolates contained 
one or two of these asp-genes located in the same region of the chromosome 
designated Locus Encoding Aerococcal Surface Protein (LASP). 
The possible synergy between benzylpenicillin and gentamicin against bacteria has 
long been an argument used in guidelines recommending combination therapy in 
infective endocarditis (IE). Two of the studies in this thesis look at this, one of 
which also describes the characteristics of IE caused by aerococci. Bactericidal 
synergy was shown against 14 of 24 streptococcal isolates and against 7 of 15 
tested aerococcal isolates. The characterisation of aerococcal IE (based on data 
from the Swedish Endocarditis Registry) showed, amongst other things, that the 
mean age was significantly higher than in IE caused by NBHS or Staphylococcus 
aureus. 
By using a cohort of Swedish patients with NBHS-bacteraemia with or without IE, 
the HANDOC score was constructed: one point given for heart murmur or heart 
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valve disease (H); one point given for an aetiology of Streptococcus bovis-group, 
Streptococcus sanguinis-group, or Streptococcus mutans-group, and one point 
subtracted for Streptococcus anginosus-group bacteraemia (A); one point added if 
the number of positive blood cultures was two or more (N); one point added for a 
duration of symptoms of seven days or more (D); one point if only one species 
was present in the blood culture (O); and one point added for a community-
acquired infection (C). Using a cut-off of two points, the sensitivity was 100% for 
detecting IE and the specificity was 76%. The HANDOC score was then validated 
in a second cohort of Danish patients with NBHS in blood culture. The HANDOC 
score and the previously published DENOVA score (originally developed to 
distinguish IE from non-IE in enterococcal bacteraemia) were then applied in 
cases of bacteraemia with Aerococcus, Abiotrophia, Gemella, and Granulicatella. 
The sensitivities of HANDOC and DENOVA were 97% and 93%, respectively, 
with specificities of 85% and 90%. Thus, HANDOC can possibly be used to 
decide whether or not to perform IE diagnostics in cases of NBHS bacteremia, and 
both HANDOC and DENOVA can possibly be used for the decision to perform IE 
diagnostics in cases of bacteremia with Aerococcus, Abiotrophia, Gemella, or 
Granulicatella. 
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Introduction 
The work included in this thesis is diverse but the general theme of endocarditis 
and endocarditis-causing organisms is a connecting thread. Ever since the 
beginnings of bacteriology in the 19th century, there has been an aim to 
differentiate and classify bacteria. Even though the famous postulates by Robert 
Koch have been modified and adapted, the underlying line of thought that different 
pathogens cause different diseases still remains relevant1. In recent decades, there 
has been great improvements in the technology used to identify bacteria, leading to 
a number of species being identified in clinical samples that were previously 
thought to be very rare. Despite this, the finding of newly discovered or re-
classified bacterial species or subspecies has not always led to an increased 
understanding about the diseases they cause or the way they do so. In this thesis, 
the overall aims are thus to describe the characteristics of several similar bacteria 
and the diseases that they cause. They all share the characteristics of being bacteria 
that were rarely identified in clinical practice until recently (making them 
emerging pathogens) or bacteria where detailed classification was not possible or 
considered necessary until recently. 
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Bacteriology and bacteriological 
methods 
In clinical bacteriology, a major goal is to detect and identify the pathogenic 
bacteria causing an infection and to determine what antibiotic treatment is likely to 
be effective against them. This chapter will describe methods that are used to this 
end in clinical bacteriology (especially as pertaining to the Gram-positive bacteria 
studied in this thesis) as well as some background on methods used in 
experimental bacteriology. 
Species identification 
The Gram stain 
The Gram stain was originally described in 1884 by the bacteriologist Hans 
Christian Gram. It involves staining the bacteria with crystal violet, adding iodine 
which binds to crystal violet and traps it in the cell. Ethanol or acetone is then 
added to decolorize. A counterstain (usually safranin) is then added. Gram-
positive bacteria are those that retain the original crystal violet stain whereas 
Gram-negative bacteria lose the crystal violet during decolorization and only 
retain the counter stain.2. Just as Gram-negative bacteria are diverse, Gram-
positive bacteria constitute a diverse group of bacteria that still have several 
characteristics in common. Morphologically, Gram-positive bacteria share the 
basic components of the cytosol, the cell membrane, and an outer cell wall. This is 
a main morphological difference from Gram-negative bacteria which have two 
membrane layers and a much thinner wall in between3,4. The thicker cell wall of 
Gram-positive bacteria contains peptidoglycan, and is the reason for Gram-
positive bacteria retaining the Gram stain and Gram-negative bacteria not doing 
so5. 
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Blood culture procedures 
Culturing bacteria from blood is the most common way of detecting bacteraemia, 
and can combine bacterial detection with species (and subspecies) determination 
and antibiotic sensitivity testing. For intravascular and cardiac infections, as well 
as infections originating at other sites where bacteraemia is suspected, taking at 
least two sets of blood cultures is recommended. A set generally consists of one 
aerobic and one anaerobic culture bottle6,7. As approximately 10 ml of blood is 
recommended to be used per bottle, this equals 40 ml of blood for bacterial 
culturing6. The volume of blood taken is important, and many studies have shown 
the relationship between the volume of blood taken and the likelihood of finding 
the pathogen in question8–10. The blood culture bottles are then incubated at 35-
37oC for 5 days. In the systems used at Skåne University Hospital (BacT/Alert 
from bioMérieux for the years 2009-2014 and BACTEC FX from Becton 
Dickinson from December 2014 and on), CO2 levels in the bottles are detected by 
a sensor and the system gives an alert when it detects increased levels of CO2 
indicating growth of bacteria. The procedure then involves direct Gram staining of 
the blood culture broth as well as inoculation into blood agar, chocolate agar, and 
agar plates optimized for anaerobic growth. Even though species identification is 
sometimes possible directly from the blood culture broth, the amplification step on 
agar is often necessary for species identification and for antibiotic sensitivity 
testing6. 
MALDI-TOF MS 
MALDI-TOF MS stands for Matrix-Assisted Laser Desorption Ionisation - Time 
Of Flight Mass Spectrometry. MALDI was first used in the 1980s to identify small 
molecules, with Tanaka et al. describing protocols for ionising larger proteins in 
1987 11–13. The principle behind MALDI-TOF MS is that the analyte (a sample 
from a bacterial colony in the clinical use of MALDI-TOF MS) is placed on a 
metal plate together with a matrix consisting of a saturated solution of a low-mass 
organic compound, often an acid. The sample is then irradiated with a laser beam. 
This causes the ionization of the analyte and a sublimation to gas phase. The 
ionized molecules are then analysed using the mass spectrometer, with the time of 
flight being used to sort the molecules by weight. This procedure is repeated many 
times per sample, with the laser targeting different parts of the spot formed by the 
analyte and matrix. This means that an average of the sample can be calculated 
and matched against a database of protein profiles for different species14. 
 The introduction of MALDI-TOF into routine use in clinical bacteriology 
represented a big shift in species identification. Before its introduction, the main 
way of identifying bacteria in culture (whether blood culture as described above, 
or bacteria cultured from urine, sputum or other sources) was based on Gram stain 
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followed by phenotypical characterisation consisting mainly of colony 
morphology and the ability to tolerate different environments such as high salt 
concentration, the ability to utilise different carbon sources, and enzymatic 
activities. This process yielded quite good exactness in many cases, but had 
difficulties in identifying some bacterial species, and was time consuming to 
perform. The use of MALDI-TOF MS has shortened the time it takes to get 
species determination, enabled the possibility to routinely identify species that 
were not possible to identify before, and decreased the granularity of bacterial 
species identification in clinical microbiology14–18. 
Sequencing 
Sequencing is the use of various methods to determine the nucleotide sequence of 
a DNA or RNA molecule such as a chromosome, plasmid, or ribosome. Though 
there were methods used to determine RNA sequences in the early 1970s and a 
whole gene of a bacteriophage was determined in 197219, the first reliable method 
for DNA sequencing was the so-called chain termination method (or Sanger 
sequencing) described in 1977. In this method, the sequence is obtained by using a 
single-stranded DNA fragment, a primer binding to the DNA at the site where 
sequencing should begin, and four separate solutions containing all four dNTP 
(deoxynucleotide triphosphate) as well as one of four di-deoxynucleotide 
triphosphates (ddTTP, ddATP, ddGTP, or ddCTP), and a DNA polymerase. When 
the polymerase adds nucleotides to the single-stranded DNA, it will stop when it 
adds a ddNTP instead of dNTP and the DNA chain will end, giving fragments of 
various lengths. The ddNTP can be labelled in various ways to enable 
determination of what nucleotide is at the end of the sequence. This means that the 
nucleotide sequence of the DNA molecule can be determined in an accurate way20. 
16S rRNA sequencing is a very important application of sequencing in clinical 
bacteriology. The 16S rRNA is the RNA of a component of the small subunit of 
the prokaryotic ribosome and is present in all bacteria. Due to this and the fact that 
the 16S rRNA is mostly species specific, sequencing of it both makes it possible to 
detect bacteria in clinical samples even after antibiotics have made culturing 
difficult and to determine the species of the bacteria21–23. When the goal is to 
separate more closely related species, 16S RNA sequencing sometimes has 
problems identifying which species it is. In those cases, multilocus sequence 
typing (MLST) is an alternative. MLST involves sequencing multiple loci, usually 
housekeeping genes, which can enable an accurate species identification even 
between closely related species and in cases of horizontal transfer of genes. The 
data from the typing is then compared to a database of know sequences from 
different species and subspecies to generate the probability that the sample belongs 
to a given species24,25. 
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Sequencing the whole genome of an organism is sometimes done to provide even 
more detail than is provided by MLST. The introduction of so-called next 
generation sequencing techniques has changed both research and clinical 
bacteriology in regard to this. Though the specific protocols differ between 
methods, the main benefit compared to chain termination sequencing is the much 
higher throughput compared to chain termination sequencing (in some cases at the 
cost of more errors), and many methods (such as Illumina sequencing) use a 
synthetisation technique instead of hybridisation to achieve this26–28. 
Antibiotic sensitivity testing 
Resistance to antibiotics is an increasing problem in treating infectious diseases, 
and has been declared by the World Health Organization to be one of the top three 
most important health issues29. Due to the fact that bacteria (both on the species 
level and individual isolates) have differing levels of susceptibility to different 
antibiotics, due to either intrinsic antibiotic tolerance or to acquired resistance, 
testing of antibiotic sensitivity is a central part of clinical bacteriology30. While 
antibiotic resistance is not a general problem when treating the bacteria discussed 
in this thesis such as, Aerococcus, Gemella, Granulicatella, Abiotrophia and the 
non-beta-haemolytic members of Streptococcus, antibiotic susceptibility still 
varies. In this chapter, aspects of antibiotic sensitivity testing and antibiotic 
synergy as pertaining to substances relevant to the studies in this thesis will be 
covered. 
General principles and guidelines 
The testing of antibiotic susceptibility of a microbial sample is done ex vivo in 
clinical practice and shows how well the antibiotic substances can hinder bacterial 
proliferation. The clinician who receives the results from the susceptibility testing 
is generally concerned whether or not the patient with the infecting organism will 
be cured when given a certain antibiotic. These are two similar but not identical 
aspects that form one of the important foundations for designing, performing and 
interpreting antibiotic susceptibility tests. 
Susceptibility testing can be done in liquid media (broth) or on solid media (agar), 
and can look at the inhibition of growth (inhibitory effect) or on the killing of 
bacteria (bactericidal effect). Broth dilution was the original way of determining 
antibiotic susceptibility and is still in use31 The method involves two-fold dilutions 
of antibiotic (e.g., 4, 2, 1, 0.5, 0.25 µg/mL) in a broth capable of sustaining 
bacterial growth. A standardised bacterial inoculum is then added to the tubes. 
After incubation at appropriate conditions, bacterial growth can be seen as 
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turbidity in the medium. The lowest antibiotic concentration that inhibits growth is 
the minimal inhibitory concentration (MIC). The European committee on 
antibiotic susceptibility testing (EUCAST) has guidelines recommending how to 
perform susceptibility testing, both when a specific protocol exists for the bacteria 
(such as NBHS and Aerococcus) and when there is no genus- or species-specific 
protocol (such as for Granulicatella, Gemella or Abiotrophia). For fastidious 
organisms, such as Aerococcus or Streptococcus, MH-F agar or broth is 
recommended for susceptibility testing. This is Mueller-Hinton medium 
supplemented with 5% defibrinated horse blood and 20 mg/ml β-NAD (β-
nicotinamide adenine dinucleotide). Incubations are to be performed in an 
atmosphere with 5% CO2 and at 37oC32. 
 
Figure 1. Etest inhibiting growth at higher antibiotic contentrations but allowing growth at lower concentrations. 
The main ways of testing on agar are the antimicrobial gradient method and the 
disk diffusion test. The antimicrobial gradient method employs a plastic or paper 
strip imbued with an antibiotic with a concentration gradient along its length. 
When this strip is placed on an agar plate with a standardized inoculum of bacteria 
and incubated at appropriate conditions, the MIC is detectable as the intersection 
of the inhibition zone and the growth zone at the strip. Testing antibiotic 
susceptibility using the disc diffusion method is similar. In this method, several 
discs infused with a specific antibiotic each at a standardised concentration is 
placed on an agar plate with a bacterial inoculum. After incubation, the zones of 
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inhibition are measured to the nearest millimetre. This gives a qualitative 
measurement of antibiotic susceptibility (susceptible, intermediate, or resistant) 
rather than an exact MIC value33,34. 
Penicillin and aminoglycosides 
The antibiotic properties of penicillin was originally discovered by Alexander 
Fleming who noted that the growth of Staphylococcus was inhibited around 
colonies of Penicillum mould on an agar plate35. The mode of action involves the 
inhibition of the D-alanine carboxypeptidase mediated through the beta-lactam 
ring, thus inhibiting cell wall synthesis36,37. One of the commonly used penicillin 
molecules is benzylpenicillin (also known as penicillin G), which is mostly 
effective against Gram-positive bacteria. As it is inactivated by gastric acid, it is 
administered intravascularly. Due to its high plasma concentration, it is used for 
infections such as endocarditis. However, since it is susceptible to beta-lactamases 
produced by some bacteria, resistance testing is important. Pharmacologically, the 
bactericidal effect is correlated with the time the antibiotic concentration is above 
the MIC value. Due to this, the dosing schedules often aim to spread the doses 
evenly during the day rather than maximising the peak concentration38. 
Another class of antibiotics are the aminoglycosides, of which gentamicin is one, 
originally derived from actinomycetes39. The antibacterial action of 
aminoglycosides comes from the binding to the16S rRNA of the ribosome40. This 
causes mistranslation and thus error-prone protein synthesis with polypeptides 
formed using the wrong amino acids. These are then released and can cause 
damage to the cell membrane and elsewhere41. The aminoglycosides have a poor 
bioavailability when taken orally and are thus given intravenously. Bactericidal 
effect is an effect of the area under the curve (AUC) of the concentration. Due to 
this and the fact that detrimental side effects such as nephrotoxicity are more 
frequent when aminoglycosides are given as multiple doses, the usual regimen is a 
single-dose-daily schedule39,42. 
Antibiotic synergy 
The concept of antibiotic synergy is not a new one and refers to cases when the 
effect of a combination of antibiotics is a large increase in bactericidal or 
bacteriostatic activity compared to each antibiotic substance in isolation 43,44. 
Testing of bactericidal synergy can be done using so-called time-kill assays where 
a bacterial inoculum is placed in nutrient broth with different concentrations of the 
tested antibiotics in combination and alone. The killing of bacteria is then 
measured by subculturing the bacteria at different time points. Another method 
using nutrient broths is the checkerboard assay. In this method, tubes of liquid 
media (or wells in a microtitre plate) are organised in a square with the 
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concentration of one antibiotic decreasing from left to right and the concentration 
of the other antibiotic decreasing from top to bottom. The MIC values of each 
antibiotic alone and in combination can be elucidated from the inhibitory zone and 
the FIC value (fractional inhibitory concentration) of each antibiotic can be 
calculated. The formula for the FIC value for antibiotic A is FICA=MICA+B/MICA, 
for antibiotic B the formula is thus FICB=MICB+A/MICB. The sums of FICA and 
FICB are added to give the FICI (fractional inhibitory index) which is an indication 
of the degree of inhibitory synergy. FICI is also possible to measure on solid 
medium such as agar plates. Antibiotic gradient strips can be used in this method 
and placed on top of each other in various combination, or with one antibiotic 
being infused in the agar and the other placed as an antibiotic gradient strip or an 
antibiotic diffusion disk44–47. 
Synergy between aminoglycosides, such as gentamicin, and penicillin, such as 
benzylpenicillin, has been shown against streptococci and enterococci48–53. The 
proposed mechanism is a weakening of the cell wall by penicillin, enabling more 
aminoglycoside to enter the bacterial cell54. There has been criticism of the 
methods mentioned above, pointing out problems such as the theoretical difference 
between inhibition of growth and killing, and the fact that two antibiotics with 
different pharmacokinetic and pharmacodynamic properties might not be present 
at relevant conditions for long in vivo even if they show synergy in vitro55. 
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Classification of Gram-positive 
bacteria 
The cell wall of Gram-positive bacteria is made up of peptidoglycan with 
lipoteichoic acid interspersed in the inner part of the cell wall (and linking it to the 
membrane) and wall teichoic acid in the outer part of the cell wall56–58. Many Gram-
positive bacteria have proteins that are anchored to the cell wall, and a common 
factor of these proteins in species related to Staphylococcus and Streptococcus is the 
LPXTG sequence in the C-terminal end59, a signal peptide,  a hydrophobic portion, 
and a charged tail60,61. These, collectively, are the cell wall sorting signal, which is 
highly conserved62. The sorting signal is recognized by sortase, a membrane-
associated enzyme that cleaves the peptide bond between the threonine and glycine 
residues and covalently binds the threonine to the peptidoglycan60,63. Other variants 
of cell surface proteins in Gram-positive bacteria are transmembrane proteins, 
lipoproteins covalently attached to membrane lipids, and cell wall proteins attached 
to cell wall domains through other methods than LPXTG-domains64. Regardless, 
many proteins considered virulence factors are LPXTG proteins, such as protein M 
and GRAB in Streptococcus pyogenes and protein A in Staphylococcus aureus65–69. 
 
Figure 2. Cladogram of the bacterial genuses discussed in the thesis 
28 
Aerococcus - a little known genus 
Aerococcus is a genus of Gram-positive bacteria in the Lactobacillales group. 
They were originally isolated from dust in 1953, with the type species being 
Aerococcus viridans. Aerococcus in clusters are morphologically similar to 
staphylococci but unlike them, aerococci are catalase-negative, and the colonies 
produced on blood agar are similar to those of streptococci70. In 1989, a new 
species called Aerococcus urinae (initially described as an Aerococcus-like 
organism) was described and was found to cause urinary tract infections and 
sepsis71–74. Since then, further species such as A. sanguinicola75, A. christensenii76, 
A. urinaehominis77, A. urinaeequi78, A. suis79, and A. vaginalis have been found80.
A. urinae was thought to be a very rare cause of human infection and was rarely
identified. One cause of this might have been the fact that they are
morphologically similar to staphylococci when grown in liquid medium and
similar to alpha-haemolytic streptococci when grown on blood agar81.
Furthermore, the Vitek system frequently misreports A. urinae as A. viridans,
while the API system and BBL-Crystal-GP provided a more certain identification.
Both Vitek and API have problems with identifying A. sanguinicola82,8384.
Sequencing the 16S rRNA gene or intergenic spacer regions is a precise method
for identifying the different Aerococcus species and separating them from each
other85, but MALDI-TOF MS has been shown to be a very accurate method that is
quicker and more easily used in a clinical laboratory86,87.
Since A. viridans was first discovered, it has been shown that different subspecies 
can cause infections in lobsters (gaffkaemia), turtles, pigs, and cows, as well as 
reports of human infections88–95, though the validity of species determination in 
case reports of human infections has been put into question96. Nevertheless, some 
case reports show infections with A. viridans where the species identification is 
certain97,98. 
The virulence factors of aerococci are mostly unstudied, but some data exist. It has 
been shown that A. urinae and A. sanguinicola can produce biofilm and cause 
antibody- and fibrinogen-dependent platelet aggregation 99,100. Genetic homologs 
for capsular polysaccharides have been identified in A. urinae and A. 
sanguinicola101, and a capsule has been identified in strains of A. viridans that 
have infected lobsters89. 
A. urinae has been shown to colonize the urinary tract of people with a urinary
catheter, and the genital area and urinary tract might be the natural habitat of the
species102. There have been many reports of aerococci causing urinary tract
infection in adults71,82,83,103–106, but cases of malodorous urine in otherwise
symptomless children have also been identified107,108. Cases of more severe
infection such as endocarditis100,103,109–113, spondylitis114,115, arthritis and other types
of invasive infection have also been described100,113,115,116. The median age of
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patients with infections by A. urinae and A. sanguinicola is quite high, with a 
median age of over 80 being reported in most studies100,106,113,115. 
Though initial studies suggested that A. urinae was resistant to trimethoprim, this 
might be due to the medium used when testing82,117–119. Urinary tract infections due 
to aerococci seem to recover clinically and microbiologically at slightly lower 
frequencies than infection due to other pathogens such as Escherichia coli, 
something that might be due to the patients with aerococcal urinary tract infections 
being older. Another possibility is that the aerococci might tolerate the antibiotics 
better despite in vitro testing showing them as sensitive, possibly due to biofilm 
formation102,106. Strains of both A. urinae and A. sanguinicola are generally very 
sensitive to penicillin, and have low MIC for cephalosporins and 
carbapenems84,119–123. Bactericidal synergy between penicillin and gentamicin 
against A. urinae has been shown in case reports, though later more robust 
investigations have shown that synergy is not universal111,112. 
Abiotrophia and Granulicatella - nutritionally variant 
Abiotrophia and Granulicatella were originally identified as so-called nutritionally 
variant streptococci and were considered part of the alpha-haemolytic streptococci 
until they were moved to the genus Abiotrophia in 1995, and then split into 
Abiotrophia and Granulicatella in 2000124–126. They lack Lancefield antigens but 
are serotypeable, with different species generally reacting to specific types of 
serum127. Invasive infection in humans has been described with A. defectiva, G. 
elegans, G. adiacens, and G. para-adiacens128–130. Species identification has 
traditionally been regarded as difficult131–135 and correctly identifying the species 
in clinical samples has been shown to be more effective when methods such as 
16S rRNA sequencing or, more recently, MALDI-TOF MS have been used in 
addition to or instead of traditional phenotypical classification129,136–138. 
Both Granulicatella and Abiotrophia are part of the oral flora and have been found 
to cause diverse invasive infections 131–135. Abiotrophia has been reported in 
infections ranging from endocarditis, spondylitis, and joint infections to central 
nervous system infections and keratitis131,139–144. Granulicatella is also known to 
cause invasive infections with a predilection for endocarditis, but is also a cause of 
meningitis, brain abscesses, implant associated infections, and osteomyelitis with 
many infections appearing after dental treatment145–150. The ability to cause 
endocarditis as well as osteomyelitis and implant associated infections might be 
connected to biofilm formation or to the ability of G. adiacens to bind fibrinogen 
151–155. 
Biofilm formation also affects the antimicrobial susceptibility, with sensitivities 
for both beta-lactam antibiotics and others decreasing greatly in the biofilm. In 
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planktonic phase, G. elegans is generally susceptible to penicillin, with G. 
adiacens and A. defective being less sensitive. Ceftriaxone has shown good effect 
against A. defectiva and G. elegans but not G. adiacens, with all three species 
being sensitive to vancomycin. They are also often sensitive to amoxicillin and 
ampicillin152,156–158. 
Table 1. List of non-beta-haemolytic Streptococcus (NBHS) species and their commonly accepted group 
classifications 
Group Species 
Mitis S. mitis 
S. pneumoniae 
S. pseudopneumoniae 
S. oralis 
S. peroris 
S. infantis 
S. australis 
S. parasanguinis 
Sanguinis S. sanguinis 
S. gordonii 
S. cristatus 
Anginosus S. anginosus 
S. constellatus 
S. intermedius 
Salivarius S. salivarius 
S. thermophilus 
S. vestibularis 
Mutans S. mutans 
S. sobrinus 
S. ratti 
S. macacae 
Bovis S. gallolyticus 
S. infantarius 
S. equinus 
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Streptococcus - not only beta-haemolysis 
Bacteria of the genus Streptococcus have long been known to cause infections. 
Though they are Gram-positive and in the Lactobacillales family, there have been 
numerous ways of classifying them such as the Lancefield system of carbohydrate 
antigens159, dividing them into α-haemolytic, β-haemolytic, and γ-haemolytic 
streptococci, as well as taxonomy based on the genetic similarity of the 
species160,161. The streptococci that are relevant to this thesis are mainly those that 
are α-haemolytic or γ-haemolytic, that is: non-β-haemolytic streptococci (NBHS). 
The phenotypic methods based on haemolysis and Lancefield antigens are still in 
common practice but have problems that are apparent upon a closer look. Species 
such as S. pyogenes are easy to classify as they uniformly express Lancefield A 
antigen and are β-haemolytic, the haemolysis being mediated through secreted 
streptolysin S and streptolysin O159,162,163. 
The NBHS are generally harder to classify using haemolysis and Lancefield 
antigens grouping systems, and there is not always consensus on what bacteria to 
include in different groups160. The bacteria in the S. anginosus group (also known 
as the S. milleri group) are an illustrative example of this. Some isolates 
considered to be S. anginosus have shown β-haemolysis, some α-haemolysis, and 
some show no haemolysis at all. These isolates can also have group A, C, G, or F 
Lancefield antigens, with some isolates having none at all164,165. Species that are 
considered to be in the S. anginosus group are S. anginosus, S. constellatus, and S. 
intermedius166. 
The question of which species to include in the S. mitis group has practical 
considerations as the spectrum of diseases they cause differ.167–171. Bacteria 
commonly included in the S. mitis group are S. mitis, S. pneumoniae, S. 
pseudopneumoniae, S. oralis, S. peroris, S. infantis, S. australis, S. 
parasanguinis172. S. massiliensis is sometimes placed in the S. mitis group, and S. 
sanguinis, S. gordonii, and S. cristatus are sometimes considered to be in the S. 
mitis group but are lately often placed in the separate S. sanguinis group (or S. 
gordonii group)171–173. MALDI-TOF MS has been useful in differentiating the 
different species in the group174,175.  
Both the S. salivarius group (consisting of S. salivarius, S. vestibularis, and S. 
thermophilus) and the S. mutans group (consisting of S. mutans, S. sobrinus, and 
S. rattus) are NHBS that are part of the normal flora and represent bacteria where 
the species determination by MALDI-TOF has improved during the recent 
years176–178. 
The S. bovis group share the D group antigen, and species that are generally 
considered to be in the S. bovis group are S. gallolyticus, S. infantarius, S. bovis, S. 
pasteurianus, S. equinus, S. macedonicus, and S. lutetiensis179–181. 
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Figure 3. Relationship between the Streptococcus groups described in the thesis171,173,176 
S. anginosus group bacteria are commonly found in the oral cavity as part of the
normal flora, but also as parts of the gastrointestinal and genitourinary flora182,183.
Haemolysis is mediated by streptolysin S (in strains with β-haemolysis) which has
a high level of similarity to streptolysin S from S. pyogenes184 whereas
intermedilysin from S. intermedius is similar to streptolysin O185. Common
infections caused by S. anginosus-group bacteria are soft tissue infections and
liver abscesses186, but cases of IE also occur167,187.
The S. mitis group of streptococci have been have also been regarded as NBHS 
with a propensity to cause IE, but with the division of the former group into the S. 
mitis group and the S. sanguinis group (where S. sanguinis is known to produce 
biofilm) it is clear that the propensity to cause endocarditis is higher in the S. 
sanguinis group 167–171,188,189. S. pneumoniae is a common cause of pneumonia and 
is also known for causing meningitis. The closely related S. mitis is a part of the 
oral flora and a rarer cause of invasive disease and lacks some of the virulence 
factors present in S. pneumoniae190,191. The capsule that is present in S. 
pneumoniae is one of these differences, though there have been findings that 
indicate that S. mitis in some cases may express a capsule and that the type of 
capsule might be of importance in infections192–194. 
Both the S. salivarius group and the S. mutans group  are part of the oral flora176. 
While S. salivarius (together with S. sanguinis, S. mitis) is associated with plaque 
formation195, S. mutans (and to some degree S. salivarius) is associated with caries 
and is a producer of biofilm176,196,197. Both S. salivarius group and S. mutans group 
streptococci have been reported to cause IE, with S. mutans seeming to be more 
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likely to do so167,170,188,198. Other types of invasive infections that have been noted 
are meningitis and joint infections199–202. 
The S. bovis group of streptococci is somewhat of an outlier compared to other 
NBHS in that it is found in the gastrointestinal tract in addition to the oral 
cavity203. An association between S. bovis group bacteria and gastrointestinal 
malignancies has been known for a long time204, though the extent of the 
association and what types of malignancies are associated has been debated203,205–
207. Similar to other types of NBHS the S. bovis group is an important cause of IE, 
both with and without valve prostheses170,208–210. 
The NBHS have many similarities, but also important differences such as 
penicillin non-susceptibility being more common in the S. mitis and S. salivarius 
groups whereas the S. anginosus, S. sanguinis, and S. bovis group have been found 
to be very susceptible. The NBHS are also generally susceptible to clindamycin 
and vancomycin211–213. 
Gemella - the odd one out 
Gemella was originally identified as a separate genus in 1961 when Gemella 
haemolysans was separated from Neisseria where it had originally been placed. 
The separation was based on Gemella being oxidase-negative, and they were 
defined as Gram-negative, facultatively aerobic and oxidase-negative cocci 
growing in pairs214,215. It was later found to be able to retain Gram stain and to 
have an architecture resembling Gram-positive bacteria, though with a somewhat 
thin cell wall216,217. Gemella has had many different places in the tree of taxonomy, 
with the type species G. haemolysans originally being considered to be one of the 
streptococcaceae216, and what is now classified as G. morbillorum was previously 
classified as S. morbillorum218. It is now placed amongst the bacilli, though it 
nevertheless has several similarities to the bacteria in the lactobacillales genus219. 
At the time of writing, seven species of Gemella have been identified in humans: 
G. haemolysans, G. bergeriae220, G. morbillorum218,221, G. taiwanensis222, G. 
asaccharolytica223, G. parahaemolysans222, and G. sanguinis224. 
Though they are a part of the normal oral flora134,225–228, both G. haemolysans, G. 
bergeriae, G. sanuinis, G. taiwanensis, and G. morbillorum have been reported to 
cause endocarditis229–237. Gemella is also known to cause abdominal abscesses, 
ocular infections, spondylodiscitis, joint infections, and spinal and cerebral 
infections238–245. 
Gemella are generally sensitive to beta-lactam antibiotics and aminoglycosides but 
resistance to macrolides and lincosamides has been found246,247. 
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Some aspects of infective 
endocarditis 
Infective endocarditis (IE) is a disease that has been recognised for quite some 
time, with a theory proposed by Sir William Osler in his 1885 Gulstonian Lectures 
that susceptible patients acquired a “mycotic” growth with spread of the 
microorganisms to other parts of the body248. It is one of the many forms of 
invasive bacterial infection, with a mortality close to 100% before the introduction 
of antibiotic treatment, and with a mortality of 15-20% even now249,250. The key 
feature of it is an infection of the heart valves (either native or prosthetic), the 
endocardium, or an indwelling cardiac device251. Even though blood is 
traditionally seen as a sterile site, the cardiac endothelium is regularly exposed to 
bacteria during activities such as tooth-brushing252. Normally, it is able to 
withstand the bacteria encountered during these episodes. If endothelial injury is 
present, the release of cytokines and tissue factors may cause a thrombus to form, 
allowing bacterial adherence and thus starting the endocarditis253. As the bacterial 
growth continues, additional damage to the endothelium occurs, starting new 
cycles of thrombus formation and the formation of a vegetation. There is also 
speculation that some bacteria also form a biofilm (a structured matrix of 
polysaccharides, DNA, and proteins), which helps with adherence and can 
increase the tolerance to antibiotics. In cases of endocarditis on prosthetic valves, 
the presence of biofilm is less controversial254,255. 
Epidemiology and microbiology 
While endocarditis remains potentially deadly, the incidence is relatively low at 3-
10 cases per 100 000 persons per year256–259. A difference in the epidemiology of 
endocarditis exists between high- and low-income countries, with rheumatic heart 
disease being a much more common risk factor in some low- and middle-income 
countries260,261. The patients are often younger and the endocarditis caused by 
streptococci from the oral flora, which contrasts to patients in high-income 
countries where instead Staphylococcus aureus is the most common cause of 
IE169,262–265. 
Cardiac prostheses such as prosthetic valves are a major risk factor for IE, and 
prosthetic valve endocarditis is an increasing problem in high-income countries. 
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Other foreign bodies such as pacemakers and implantable cardioverter-
defibrillators (ICD) are also an increasingly common risk factor for IE in high-
income countries 256,266,267. The microbial spectrum is somewhat different in high-
income countries as compared to low-income ones, with most studies describing S. 
aureus as being the most common cause of IE and with streptococci as the second 
most common group169,250,258,268–270. The streptococci most commonly associated 
with IE are the so-called viridans group streptococci (including Streptococcus 
mitis, Streptococcus mutans, Streptococcus sanguinis, Streptococcus anginosus, 
and Streptococcus salivarius) and the group D streptococci (including amongst 
others Streptococcus bovis)251,271, but other streptococci such as S. dysgalactiae are 
also found272. The third main group of bacteria causing IE is the enterococci with 
most cases being caused by E. faecalis251. More uncommon causes causing IE are 
the Gram-negative bacteria in the HACEK group (consisting of the Haemophilus, 
Aggregibacter, Cardiobacterium, Eikenella, and Kingella genera)273, and Gram-
positive bacteria such as Abiotrophia, Aerococcus, Corynebacterium, Gemella, 
and Granulicatella 112,138,274–278. 
Diagnosing endocarditis 
The diagnosis of IE is based on a combination of clinical findings, microbiological 
data, and imaging results. The modified Duke criteria include these three domains 
and are the most commonly used definition of endocarditis279,280. Microbial 
diagnosis is most commonly made through blood cultures, but can also be made 
by culturing valve biopsies, serology, or PCR. When using blood cultures for 
microbial diagnostics in IE, taking more cultures increases the sensitivity8,281–283. 
Blood cultures are the main method for more common causes of IE such as 
coagulase-negative Staphylococcus, S. aureus, NBHS, and other streptococci, 
Enterococcus, and the HACEK bacteria. Microbiological diagnosis of blood 
culture negative IE is more challenging, but methods such as serology and PCR on 
heart valves can identify bacteria such as Coxiella burnetii, Bartonella spp., and 
Tropheryma whipplei. In some cases, specialised growth medium and specific 
incubation condition can be used, such as in IE caused by mycobacteria or 
fungi282. 
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Table 2. 
The modified Duke criteria for IE279,280. 
Major criteria    
 Blood culture positive for IE  
Typical microorganisms 
consistent for IE from 2 
separate blood cultures 
  or 
Microorganisms consistent 
with IE from persistently 
positive blood cultures 
  or 
Single positive blood 
culture for Coxiella burnetii 
or antiphase I IgG antibody 
titer >1:800 
 Evidence of endocardial involvement   
 Echocardiogrram positive for IE  
Oscillating intracardiac 
mass on valve or on 
supporting structures, in the 
path of regurgitant jets, or 
on implanted material in the 
abscence of an alternative 
anatomical explanation 
  or Abscess 
  or New partial dehiscence of prosthetic valve 
Minor criteria    
 Predisposition  Predisposing heart condition 
  or Intravenous drug use 
 Fever, temperature >38oC   
 Vascular phenomerna   
 Immunologic phenomena   
 Microbiological evidence  
Positive blood culture that 
does not meet the criteria 
for a major criterion 
  or 
Serological evidence of 
active infection with 
organism consistent with IE 
 
Echocardiography is the main method used to localise vegetations on the heart 
valves as well as to identify valvular damage and abscesses. TTE (transthoracic 
echocardiography) can be used to find microbial vegetations, but the sensitivity 
and specificity of TEE (transoesophageal echocardiography) makes it the preferred 
modality in IE investigations284,285. When the suspicion of IE is high, a TEE with 
normal findings can be repeated after 7-10 days. Further investigations can add 
information but only in a minority of cases286,287. Echocardiography is also the 
main method of identifying infections of cardiac devices288,289. 
The question is when to raise the suspicion of IE? Some factors are known to 
increase the risk that a bacteraemia is associated with IE. Much of the research that 
has been done concerns S. aureus bacteraemia, but also Enterococcus and 
streptococcal species. The time it takes until a blood culture is reported positive by 
the automated detection systems ("time to positivity") has been shown to be 
inversely related to the risk of IE in case of S. aureus bacteraemia, that is, a shorter 
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time until the culture turns positive means a higher risk of IE290–292. Other factors 
known to be associated with an increased risk that a bacteraemia is caused by IE 
are the presence of a cardiac implantable electronic device, secondary foci (such as 
spondylodiscitis), embolization, or if the patient is receiving haemodialysis293–295. 
The implementation of these results, together with other data, into formalised 
score systems were later published as the PREDICT and VIRSTA scores in an 
attempt to guide whether or not to suspect IE in case of S. aureus 
bacteraemia296,297. For Enterococcus bacteraemia, known risk factors for IE are 
male sex, community acquisition, the presence of a valvular prothesis, unknown 
focus of infection, monobacterial infection, and multiple positive blood cultures. 
Some of these factors were included in the NOVA score which attempted to 
identify patients with bacteraemia but with a low risk of IE where IE 
investigations were unnecessary. As can be seen, there are many factors that are 
common between bacteria that increase the likelihood that bacteraemia is 
associated with IE, and some that seem to be more important when the 
bacteraemia is caused by certain bacteria 298–303. The NOVA score was later 
refined and the DENOVA score published, which increased the specificity for 
detecting IE while retaining a high sensitivity304. 
Other imaging modalities may also be used in process of diagnosing IE. Multislice 
computed tomography (CT) was originally used to diagnose complications of IE, 
such as ischemic lesions caused by embolism305. Cardiac tomography can also be 
gated by electrocardiogram to investigate lesion in cases of suspected prosthetic 
valve IE or to explore the anatomy preoperatively306,307. CT can also be used in 
cardiac imaging to find valve abnormalities and vegetations, and may be superior 
to TEE in patients with calcified valves or in the assessment of the extent of 
perivalvular abscesses or pseudoaneurysms308–310. MRI is also a modality that can 
be used to diagnose asymptomatic embolization, which can affect both diagnosis 
and choice of management311,312. Both CT and MRI (magnetic resonance imaging) 
imaging of the brain can be used to detect embolization both to confirm a 
suspicion of IE (as it confirms one of the Duke criteria) and to aid in the 
prognostication. Nuclear imaging is another modality that is used in the 
management and diagnosis of IE, and the finding of increased uptake around the 
valves using 18F-fluorodeoxyglucose positron emission tomography-CT has been 
proposed as a major criterion for the diagnosis of IE, though not without 
criticism308,313–315. 
Treatment and other clinical aspects 
Treatment of endocarditis is based on antibiotic therapy with surgery performed 
when needed to replace damaged valves and as source control316,317. Treatment has 
traditionally been performed as long regimes of intravenous antibiotics. For 
bacteria such as Enterococcus and Streptococcus, therapies combining beta-lactam 
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antibiotics and aminoglycosides have been common with the possibility of 
shortening the necessary treatment time being given as the reason313,318. Both 
European and American guidelines have also recommended a combination therapy 
for IE caused by Abiotrophia and Granulicatella 313,318. This is something that has 
been put into question by recent studies, and combinations of different beta-
lactams or beta-lactams combined with daptomycin have been tried319,320. Recent 
studies indicate that oral treatment might be a safe and effective option for IE in 
stable patients without complicating factors321,322. In cases of prosthetic valve 
endocarditis, the antibiotic treatment is often longer than in cases of native valve 
endocarditis, though the antibiotics of choice remain the same except when the 
causative organism is S. aureus, in which case the addition of rifampicin and 
gentamicin is recommended255. 
Complications that might occur depend on the location of the infection, underlying 
conditions, and on the infecting pathogen. Common serious complications include 
valve damage with consequent heart failure, embolization to end arteries with 
ischemia and stroke, and metastatic infections such as spondylodiscitis. These 
complications are the reason for much of the mortality and morbidity of 
endocarditis255,295,323. The question of when to perform surgery is one of the major 
ones in the management of IE. In cases such as patients with valve damage and 
heart failure, high risk of embolization, or infections with highly resistant 
microorganisms, the consensus is that surgery is to be performed. Results from 
different studies diverge on the importance of early surgery, possibly due to 
different patient characteristics in different studies. A recent meta-analysis does 
show that early surgery decreases mortality, and other studies emphasise the 
importance of surgery in cases of heart failure. There is also some evidence that 
the type of infectious agent might affect surgical outcome. As the decision on if 
and when to perform surgery, what kind of imaging to use and when, and what 
kind of antibiotics to use and for how long are difficult, a close collaboration 
between different specialities is needed to handle this complicated infection 
properly313,324–332. 
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Present investigations 
Paper I 
Identification of two abundant Aerococcus urinae cell wall-anchored proteins 
When work started on this paper, very little was known about the virulence 
mechanisms of A. urinae. The aim was to explore the surface proteome in the hope 
of finding possible mechanisms through which the bacteria cause infection. 
Surface proteins are an interesting subject to study as they are often important for 
virulence, such as being used for adhesion to surfaces, attachment to cells, or due 
to being a part of a capsule. They are also often important in the immune response 
and potentially of interest as a vaccine target. The initial study was done through 
mass spectrometry, and two surface proteins named Aerococcal surface protein 
(Asp) 1 and 2 were identified and found to quantitatively dominate the bacterial 
surface. The presence of these protein was also shown using ELISA with serum 
from rabbits immunized with recombinantly expressed Asp 1 and 2. These 
proteins had a signal sequence in the amino-terminal end as well as a wall-sorting 
sequence in the carboxy-terminal end with an LPATG-motif, a lipophilic domain 
and a positively charged tail. In total, twenty-five A. urinae genomes were 
sequenced using an Ilumina HiSeq system. Six different variants of the genes 
(asp1-6) were found. All studied isolates had one or two asp-genes located in the 
conserved locus denoted Locus encoding Aerococcal Surface Proteins (LASP). 
The original plan was to study their function by knocking out the asp 1 and asp 2 
genes. Sadly, despite a great deal of effort, we were unsuccessful in knocking out 
the asp 1 and asp 2 genes and we had to settle for a more descriptive study. Cell 
wall-anchored proteins with LPXTG-domains are a common virulence factor in 
Gram-positive bacteria. Thus, despite our goals being to characterise the function 
of the Asp proteins even further, the finding and characterisation of these proteins 
and genes are an important step in the mapping of aerococcal molecular virulence 
mechanisms.  
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Paper II 
Clinical and microbiological features of infective endocarditis caused by aerococci 
Antibiotic treatments for IE combining beta-lactam antibiotics with 
aminoglycosides have been common for decades, despite limited evidence for the 
usefulness of such combinations. The reasoning used is a supposed bactericidal 
synergy between beta-lactam antibiotics and aminoglycosides against Gram-
positive bacteria, something which has been shown in vitro for certain bacteria 
such as Entercococcus but has not been demonstrated for many other species. The 
lack of evidence is more pronounced when it comes to emerging pathogens such 
as Aerococcus where the only study published before this was a description of two 
cases of IE with killing kinetics described111. This lack of knowledge combined 
with the lack of more systematic descriptions of endocarditis caused by aerococci 
formed the background behind this study. The fact that previous studies describing 
aerococcal IE were mostly case reports increased the importance of a more 
organised study such as this, as case reports are more likely to be written in cases 
of a dramatic course of disease or in cases with unusual types or localisations of 
infection thus skewing the published data. The Swedish Registry of Infective 
Endocarditis (SRIE) was used to find cases of aerococcal IE between 2002 and 
2014. Fourteen cases of IE caused by Aerococcus urinae and two cases of IE 
caused by A. sanguinicola were identified and the species identification was 
confirmed using MALDI-TOF MS. The medical data was then studied and 
compared to cases of IE reported to the SRIE caused by other bacteria. Antibiotic 
sensitivity to various antibiotics was tested using Etests and synergy between 
benzylpenicillin and gentamicin was tested using broth microdilution with 
different concentrations of benzylpenicillin and measuring at 0, 6, and 34 hours. 
The data showed that patients with aerococcal IE on average were older than 
patients with IE caused by non-beta-haemolytic streptococci or Staphylococcus 
aureus. 75% of the patients with aerococcal IE were men. An interesting aspect of 
the study is that all patients had received a combination of penicillin and an 
aminoglycoside. In vitro bactericidal antibiotic synergy was, however, only shown 
for 7 of the 16 isolates, which makes this the first study to systematically describe 
antibiotic synergy against aerococci. The reasoning behind the decision to treat the 
patients with a combination of a penicillin and an aminoglycoside is not known 
with any certainty, but it is possible to speculate. Perhaps the decision was based 
on the presumed synergy between penicillin and aminoglycosides against 
enterococci and streptococci? Regardless, it shows the importance of studying 
pathogenic bacteria systematically instead of relying on case reports, and instead 
of assuming that they behave identically to their relatives. This study provides 
valuable clinical information about aerococcal IE as well as an indication that 
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meaningful antibiotic synergy might be possible but also definitely not certain in a 
given isolate. 
Paper III 
Antibiotic synergy against viridans streptococci isolated in infective endocarditis 
Guidelines for IE caused by viridans (or non-beta-haemolytic) streptococci have 
often recommended combining beta-lactam antibiotics with aminoglycosides. The 
basis for this has been clinical practice as well as a limited amount of animal 
studies where antibiotic synergy has been shown, together with old clinical studies 
where the controls were not fully comparable to the patients receiving combination 
treatment. Since aminoglycosides have well known side effects such as 
ototoxicity, we wanted to determine if it was possible to show bactericidal synergy 
between benzylpenicillin and gentamicin in vitro as well as see if bactericidal 
synergy was associated with bacteriostatic synergy. The idea was to see if it was 
possible to determine if this synergy was possible to detect using methods that 
would be easy to implement in routine use at clinical microbiology laboratories. 
This would allow the use of gentamicin to be restricted to cases with proven 
synergy and spare other patients a potentially toxic treatment. 
24 of viridans group streptococci were collected from patients that had been 
treated for IE at Skåne University Hospital and the species determination 
confirmed by MALDI-TOF MS. Antibiotic sensitivity was then tested using Etests 
and broth microdilution. Fractional inhibitory concentration (FIC) for 
benzylpenicillin and gentamicin was then tested using Etests. Bactericidal synergy 
was tested using broth microdilution with two different concentrations of 
benzylpenicillin combined with gentamicin, measured at 0, 6, and 24 hours. 
Bactericidal synergy was shown in 14 of 28 isolates. Bacteriostatic synergy as 
determined by FIC was shown in 2 out of 24 isolates, none of which sowed 
bactericidal synergy. This means that antibiotic synergy is present in some isolates 
at least in vitro but the clinical applicability is uncertain. The question if in vitro 
synergy can be assumed to correlate to an increased synergy in vivo remains, as 
does the question if lack of synergy in vitro (as defined in this study) means that 
there is no appreciable effect in vivo if gentamicin is added to benzylpenicillin in 
treatment. The difference between FIC values and bactericidal synergy might be 
due to differences between solid and liquid media. Regardless of the mechanistic 
reason for the difference, it means that there is no easy way of testing antibiotic 
synergy in clinical practice. In the 2015 European guidelines for IE, a combination 
of a beta-lactam antibiotic and an aminoglycoside is one of the recommended 
antibiotic treatments for streptococcal IE in cases where the renal function is good. 
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In one of the studies cited in the guidelines, relapse was noted in a case of 
endocarditis with a bacterium where no in vitro synergy was seen. This, together 
with the clinical studies cited presenting patients with complications from the 
ototoxic and nephrotoxic effects of aminoglycosides show the need of ascertaining 
whether or not there truly is synergy if a combination treatment is to be used313,333–
335. Data from the POET (Partial Oral Treatment of Endocarditis) study show that
short intravenous antibiotic therapy followed by oral antibiotic treatment is a
promising alternative to short-term combination therapy with beta-lactams and
aminoglycosides if no good way to determine actual synergy can be found321.
Paper IV 
HANDOC: a handy score to determine the need for echocardiography in non-β-
haemolytic streptococcal bacteraemia 
As can be inferred from the Duke criteria, a combination of echocardiography and 
microbiological testing is used to diagnose endocarditis. A question thus arises 
when a clinician is confronted with a blood culture showing growth of a bacterium 
that can cause endocarditis: when should you perform further investigations for IE 
and when should you look elsewhere for the source of the bacteraemia? Scoring 
systems that try to identify patients with low risk for IE (and thus without need for 
further IE investigations) have been developed for IE caused by Staphylococcus 
aureus and enterococci with varying degrees of success. Despite non-beta-
haemolytic streptococci (NBHS) being a quite common cause of IE, they also 
cause other infections where different investigations are needed. To rectify this, 
we decided to perform a retrospective study of patients with bacteraemia caused 
by these streptococci. Patients in Skåne showing growth of NBHS in blood culture 
between 2012 and 2014 were identified. Patients under 18 years of age were 
excluded, as were patients with neutropenia or where the medical records were 
unavailable. They were then divided into two groups with the patients with blood 
cultures from January 2012 to June 2013 used to generate the score. Species 
identification was confirmed using MALDI-TOF MS. The first cohort consisted of 
339 patients of whom 26 had IE as defined by the modified Duke criteria. Since IE 
can have many symptoms and the diagnostic process can have ambiguous results, 
patients were put into three groups. One group was those where IE was confirmed 
according to the Duke criteria, one group included patients where IE could be 
excluded (i.e., by TEE without signs of IE), and one group consisted of patients 
that did not meet the Duke criteria for IE but where IE could not strictly be 
excluded (i.e., patients where TTE and TEE was not performed but received a long 
antibiotic treatment that might be curative for IE). 
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Figure 4. Flowchart describing the inclusion process for the study. 
Several factors differed between those that had IE and those that did not. Among 
these factors, the presence of heart murmur or heart valve disease (H), aetiology 
with the groups of Streptococcus mutans, Streptococcus bovis, Streptococcus 
sanguinis, or Streptococcus anginosus (A), number of positive blood cultures ≥2, 
duration of symptoms of 7 days or more, only one species found in blood culture, 
and community acquisition of the infection were used to form the HANDOC score. 
One point was given for each of the components in the score except aetiology of S. 
anginosus where one point was subtracted instead. Using a cut-off between 2 and 3 
points, the sensitivity was 100% and the specificity was 73% for identifying patients 
with IE. 
To validate the HANDOC score, the second half of the population was used, 
which comprised of patients whose blood cultures were received between July 
2013 and December 2014. 522 blood cultures were received during that period, 
and the same inclusion and exclusion criteria as in the main cohort were used. 
When comparing patients with and without IE in this cohort, the HANDOC score 
had a sensitivity of 100% and a specificity of 76%. This means that it might be 
possible to use HANDOC in clinical practice to identify patients with a very low 
446 patients
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339 patients 
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26 IE
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117 unknown
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9 not NBHS
13 records
unavailable
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risk of IE and thus direct the use of echocardiography resources to cases where the 
risk is higher. A criticism that was published was regarding the group where the IE 
status was classified as unknown. Similar studies have generally classified all 
cases which did not fulfill the Duke criteria as non-IE. While it remains possible 
that cases of IE were missed and placed in the “unknown” group, this reflects the 
clinical difficulties in establishing a certain IE diagnosis. The few patients in the 
“unknown” group who received a clinical diagnosis of IE all had HANDOC scores 
of 3 or more, which might indicate that HANDOC would not miss cases of 
infection where the IE status is uncertain336,337. Another possible problem is the 
overlap between the Duke criteria and the HANDOC score, such as two positive 
blood cultures being a criterion for IE in the Duke criteria as well as one of the 
parts of the HANDOC score. While this causes a possible circle reasoning, only 
one of the IE cases in the study would have been classified otherwise if they had 
had only one positive blood culture. That patient had 6 out of 6 possible points in 
HANDOC and indicates that the success of HANDOC is not only due to the 
criteria being similar to the Duke criteria. Similarities between the scoring systems 
are difficult to avoid as they concern the same clinical condition. The division of 
the NBHS into groups is one of the strengths of the study and shows the 
usefulness of improved microbiological capabilities. Separating the S. mitis group 
from the S. sanguinis group can be seen as somewhat controversial as they have 
traditionally been placed together. However, new genetic data as well as their 
different predilections for causing IE show that separating them into different 
groups makes sense both from a scientific and a practical point of view. Looking 
at single streptococcal species might have revealed even more differences in the 
risk for IE in bacteremia, but would have necessitated a larger cohort and even 
more certain species determination. All in all, HANDOC represents a scientific 
study of a potential implementation of a systematic use of microbiological and 
clinical data into clinical use. The usefulness might be greatest in hospitals where 
there is no in-house capability for TEE at all and where the patients thus must be 
sent to other hospitals when TEE is indicated. 
Paper V 
External validation of the HANDOC score–high sensitivity to identify patients with 
non-beta-haemolytic streptococcal endocarditis 
The investigations presented in Paper IV showed that the HANDOC score had a 
very high sensitivity and a good specificity. A drawback with regards to 
generalizing the results is that both the group of patients used to generate the 
HANDOC score and the group used to validate it come from the same 
geographical area. This means that one can expect similar patient characteristics in 
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both groups, but also that patient selection, routines for when to take blood 
cultures, availability of TEE, and possibly also the physicians that documented 
their findings in the medical records were the same in both groups, which possibly 
limits the generalisability. A study was thus performed where the patient data was 
collected at Herlev-Gentofte Hospital and North Zealand Hospital in Denmark. 
Patients with NBHS in blood culture between March and September 2016 were 
included as part of an ongoing study where data on all patients with Gram-positive 
cocci in blood cultures was collected. TTE and TEE were recommended according 
to local guidelines when blood culture showed growth of Gram-positive bacteria 
typically found in IE. I thus went through the medical records of the patients with 
NBHS and classified the patient data and microbiological findings in the same 
way as in Paper IV. The HANDOC score was applied without modifications. In 
total 68 patients were included, 16 of which had confirmed IE. When the 
HANDOC score was used to separate patients with IE from those without, in this 
setting, the sensitivity was 100% and the specificity 59%. This shows an excellent 
sensitivity and an acceptable specificity. The lower specificity and positive 
predictive value in this study as compared to Paper IV might plausibly be due to 
blood cultures being taken from a different proportion of patients as well as there 
being a lower amount of polymicrobial findings in culture, indicating either a 
better technique for blood drawing or different laboratory conditions. Another 
limitation is the small size of the study population, limiting the power in regards to 
evaluating HANDOC in cases of less common NBHS variants. Just as in Paper IV, 
the small size of the study population hinders any analysis of single NBHS 
species. Despite these limitations, I consider this study an indication that 
HANDOC might be of use in other regions as well. 
Paper VI 
Risk for endocarditis in bacteraemia with Streptococcus-like bacteria, a 
retrospective population-based cohort study 
Gram-positive bacteria are a known and common cause of IE. The amount of 
information available about IE caused by different species is uneven, with the risk 
of IE by bacteria such as Staphylococcus aureus and Enterococcus being quite 
well studied. The risk of IE due to streptococci was explored in Papers IV and V. 
As described in Paper II, aerococci are also a possible cause of IE. The aim of this 
paper was to study the risk of IE in bacteraemia with so-called Streptococcus-like 
bacteria such as Aerococcus, Abiotrophia, and Granulicatella in the 
Lactobacillales order as well as Gemella in the Bacillus order. Blood cultures 
positive for Aerococcus, Gemella, Granulicatella, or Abiotrophia between January 
2012 and December 2017 were identified in the databases of the Clinical 
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Microbiology Laboratory in Region Skåne and from Karolinska University 
Hospital as part of a collaborative study. Patients under the age of 18 were 
excluded, as were those whose medical records were unavailable. Information 
from the medical records was collected and the data was categorised according to 
the NOVA301, DENOVA304, and HANDOC188 scores. These scoring systems were 
originally designed for separating patients with and without IE in bacteraemia with 
enterococci (NOVA and DENOVA) or streptococci (HANDOC). The aetiology 
(A) variable in HANDOC originally refers to which streptococcal group is found
in blood culture. To be able to apply the score to other bacteria, the proportion of
IE in bacteraemia with Abiotrophia, Aerococcus, Gemella, and Granulicatella was
compared to the proportions in the HANDOC study. Abiotrophia defectiva was
found to be significantly more likely to cause IE while Aerococcus sanguinicola
was less likely to do so. Thus one point was given for A. defective for A in the
HANDOC score, one was subtracted for A. sanguinicola and the remaining
species were given zero points. In addition to testing the risk cores, outcome and
risk factors for IE were also studied.
The risk for IE in bacteraemia with Abiotrophia was found to be 21% in this study, 
which is higher than many other species that are known for causing IE, such as S. 
aureus, E. faecalis and NBHS. The NOVA score had a sensitivity of 100% but the 
specificity was only 15,5%. Both the HANDOC score and the DENOVA score 
had a high sensitivity (97% and 100%, respectively, and also a high specificity 
(85% and 61%, respectively). This study is the first systematic study of the risk of 
IE in bacteraemia cases with Abiotrophia, Granulicatella and Gemella, and the 
second published study on risk of IE in bacteraemia cases with Aerococcus. The 
results show that the risk of endocarditis is highly species-dependant. The most 
obvious example is the very high risk of IE in bacteraemia with Abiotrophia, but 
also the difference in risk of IE between Aerococcus urinae and Aerococcus 
sanguinicola. To conclude, this study showed that it should be possible to use both 
HANDOC and DENOVA to inform the need for IE investigations in bacteraemia 
with Streptococcus-like bacteria (SLB), and also that the characteristics of IE 
caused by SLB is similar to IE caused by enterococci and streptococci. The study 
also shows the utility of exact species determination in clinical decision making. 
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Conclusions and future perspectives 
The general awareness of the bacteria studied in this thesis was low when I started 
the work presented herein, especially regarding the Aerococcus genus and 
aerococcal infections. With MALDI-TOF MS having become the primary method 
of species determination in clinical bacteriology, the number of species and 
subspecies that are possible to identify and report to the clinician has increased 
tremendously. Despite this, there was of a lack of scientific data about what these 
emerging pathogens represented clinically. During the course of this work, 
Aerococcus has gone from a pathogen that was mostly known by a small group of 
bacteriologists to a clinically known and relevant genus, and the groups of NBHS 
have been recognised to have different predilections to cause IE and other disease. 
The work on determining the clinical differences in bacteraemia caused by other 
Gram-positive cocci such as Gemella, Granulicatella, and Abiotrophia has also 
increased during this time. While the classification and identification of these 
bacteria has been more or less known, the works in this thesis (along with many 
other scientific investigations) have shown the clinical utility of the improved 
species identification available. The works presented here have studied the case of 
species identification in endocarditis diagnosis in particular, but further studies 
might show the utility in other cases. 
The results from Papers IV-VI have implications beyond the need for accurate 
species determination in clinical bacteriology. Though some studies have 
recommended echocardiography in all cases of blood stream infection with 
Streptococcus and similar species338, the data from these studies suggest that 
echocardiography could be omitted in certain cases based on bacterial species but 
also clinical findings. The clinical findings in question, such as the finding of a 
heart murmur or the presence or lack of a focal infection, are parameters that have 
been known to clinicians and described scientifically before but have not been 
aggregated and formalised until recently. The implementation and optimisation of 
such management scores and algorithms warrant further study. 
In addition, the further characterisation of new bacteria such as Aerococcus urinae, 
both molecularly and clinically, has provided clinically important data and venues 
for further studies. The LASP genes encoding the Asp proteins are arranged in a 
way that has a striking similarity to the M proteins of Streptococcus pyogenes. It is 
possible that the Asp proteins have a similar function in aerococci, or that they 
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function as adhesion factors to urothelium or other surfaces. Further studied are 
needed to determine this. 
In a perhaps more visionary perspective, this thesis shows the interconnectedness 
of microbiology in the laboratory and the practice of treating infectious diseases 
clinically. Many of the projects in this thesis have utilized data that is already 
possible to obtain from clinical microbiology laboratories. This, in my opinion, 
stresses the need for utilization of the information that is available. There is a trove 
of information available that might improve patient outcomes if only we knew 
how to utilise it. If identification—not only on the species level, but also on the 
subspecies level—becomes generally available, the prospect of further tailoring 
diagnostic procedures and treatments becomes possible. Examples of this could be 
choosing treatment length, dosing regimens and antibiotic combinations based on 
bacterial species, antibiotic synergy patterns, as well as the existence of virulence 
factors or the ability of the bacterial isolate to produce biofilm. The continuing 
research into these areas have great potential and is necessary in the face of threats 
such as antibiotic resistance. 
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Populärvetenskaplig sammanfattning 
Bakterier är en sorts mikroorganismer där en del orsakar sjukdom hos människor 
och djur, och en del lever på och kring oss utan att orsaka skada. En del bakterier 
lever i munnen, andra på huden, i tarmen eller kring urinvägarna. I denna 
avhandling berörs bakterierna i släktena Aerococcus och Streptococcus, samt de 
besläktade bakterierna Abiotrophia, Gemella and Granilucatella. Alla dessa 
bakterier finns normalt sätt på och i oss men kan i vissa situationer orsaka 
sjukdom. 
Bakterier är encelliga varelser som är betydligt mindre än kroppens egna celler. 
Gemensamma drag är att de har sitt DNA i en enda kromosom och oftast har en 
cellvägg runt sitt cellmembran. Ett sätt att dela upp bakterier är i så kallat Gram-
positiva och Gram-negativa bakterier. Uppdelningen baseras på hur bakterierna 
färgas av ett speciellt färgämne och beror på hur deras cellväggar och 
cellmembran är ordnade. Gram-negativa bakterier har en tunn cellvägg av 
peptidoglykan kring sitt cellmembran med ett andra membran utanför, medan 
Gram-positiva bakterier enbart har cellmembranet samt en tjock cellvägg av 
peptidoglykan. Bakterierna Aerococcus, Abiotrophia, Gemella, Granilucatella och 
Streptococcus är alla Gram-positiva bakterier. Gram-färgning ger dock bara en 
väldigt grov uppdelning av bakterier och man har även använt sig av saker så som 
vilken form bakterier har, under vilka betingelser de växer och vilka ämnen de kan 
bryta ner för att klassificera och identifiera dem. Även dessa sätt har dock 
begränsningar, och man hade därför svårt att identifiera aerokocker, och tolkade 
Abiotrophia och Granilucatella som en sorts streptokocker. Med så kallad 
MALDI-TOF-teknik där man analyserar proteinmönstret i bakterien har detta 
blivit mycket lättare och man ser nu att framför allt aerokocker är klart vanligare 
än man hade trott. Eftersom man tidigare har haft svårt att hitta och identifiera 
aerokocker i prov från människor har man heller inte studerat dem särskilt mycket. 
Det gör att man bland annat inte har vetat vilka proteiner som sitter i deras 
cellvägg. Arbetet med att studera dessa är ett av projekten som beskrivs i 
avhandlingen. Här identifierades två proteiner hos bakterien Aerococcus urinae 
och vi kunde konstatera att de satt i bakteriens cellvägg och var mycket lika 
varandra. 
Dessa bakterier kan orsaka olika sjukdomar där en av de mest allvarliga är 
hjärtklaffsinfektion, endokardit. När detta sker bildar växer bakterierna på hjärtats 
klaffar i klumpar, så kallade vegetationer, samt på hjärtats insida, endokardiet. 
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Innan antibiotikabehandling fanns var detta en sjukdom som i praktiken alltid 
ledde till döden. Detta förändrades när penicillin och andra antibiotika kom, men 
dödligheten är fortfarande hög. Traditionellt har man valt att behandla endokardit 
orsakad av dessa bakterier med långa antibiotikakurer med en kombination av 
betalaktamantibiotika (där penicillin ingår) och aminoglykosider (som är en annan 
sorts antibiotika). Anledningen har varit att man har tänkt att kombinationen av 
dessa antibiotika har en så kallad synergistisk bakteriedödande effekt, där de olika 
typerna av antibiotika ihop har en klart kraftigare effekt en de har var och en för 
sig. För aerokockendokardit har det funnits väldigt lite systematisk beskrivning av 
förlopp och inga studier kring om kombinationsbehandling har effekt. I en av 
studierna gjordes därför en systematisk genomgång av data från svenska 
endokarditregistret där fall av aerokockendokardit jämfördes med endokardit 
orsakad av andra bakteriearter. Dessutom jämfördes kombinationsbehandling (i 
provrör) med penicillin och aminoglykosid mot vardera antibiotikum för sig. Man 
såg att det var en överrepresentation av äldre män bland patienterna med 
aerokockendokardit och att synergi sågs hos vissa men långt ifrån alla isolat. En 
annan studie i avhandlingen undersökte på liknande sätt antibiotikasynergi mot 
streptokockisolat från patienter med endokardit. Även i denna studie såg man 
antibiotikasynergi hos vissa men inte alla isolat. 
Ett praktiskt problem för sjukvården är att bakterier från släkterna Aerococcus, 
Abiotrophia, Gemella, Granulicatella samt Streptococcus inte bara orsakar 
endokardit utan även andra sorters infektioner. När man hittar dem i blodet är det 
således inte helt enkelt att veta vilken sorts infektion som ligger bakom. Ett sätt att 
ta reda på detta är genom att undersöka hjärtat med ultraljud där sensorn placeras i 
matstrupen i hjärthöjd, så kallad transesofakal ultraljudsundersökning (TEE). 
Detta är dock en undersökning där kompetensen för att genomföra den är 
begränsad till vissa sjukhus och med begränsad kapacitet, samt som dessutom är 
en inträngande och obehaglig undersökning för patienten. Tre av studierna i 
avhandlingen berör därför endokardit och när risken för detta är så hög att 
utredning behövs. En population med patienter som hade streptokocker i blodet 
studerades därför och riskklassificeringssystemet HANDOC togs fram. Genom att 
bedöma om patienten hade hjärtklaffsjudkom eller blåsljud på hjärtat (H, "heart 
murmurs or heart valve disease"), vilken streptokockart som låg bakom 
infektionen (A, "aetiology"), antal fynd i blododling (N, "number of positive 
cultures"), symptomduration (D, "duration"), om det var en eller flera bakteriearter 
i odlingarna (O, "only one species") samt om infektionen var samhällsförvärvad 
(C, "community acquired") kunde man skilja vilka patienter som hade endokardit 
från de som inte hade det med hundraprocentig sensitivitet och god specificitet. 
Med sensitivitet menas andelen av de som faktiskt hade endokardit som metoden 
korrekt identifierade som personer med endokardit, och med specificitet menas 
andelen av de som inte hade endokardit som metoden korrekt identifierade som 
personer utan endokardit. Detta innebär att HANDOC skulle kunna användas för 
att på ett säkert sätt sortera ut patienter som har så låg risk för endokardit att 
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endokarditutredning inte behöver göras. Detta poängsystem prövades och 
kvaliteten bekräftades sedan externt i en studie med data från en grupp danska 
patienter. Även i detta fall såg man en hundraprocentig sensitivitet och en hög 
specificitet. 
I avhandlingens sista arbete testades HANDOC samt riskstratifieringssystemet 
DENOVA (framtaget för att bedöma risk för endokardi vid bakteriemi med 
Enterococcus) på patienter med Abiotrophia, Aerococcus; Gemella och 
Granulicatella i blodet. Patientdata samlades in från journaler i Skåne och 
Stockholm och patienter med och utan endokardit testades i poängsystemen. 
DENOVA hade en hundraprocentig sensitivitet och HANDOC en sensitivitet på 
nästan hundra. Båda hade en acceptabel specificitet, där specificiteten för 
HANDOC var högre. 
Sammanfattningsvis har jag i denna avhandling studerat ytproteiner hos de allt mer 
uppmärksammade och endokarditorsakande bakterierna Aerococcus, testat 
antibiotikasynergi mot Aerococcus och Streptococcus, tagit fram samt validerat 
riskbedömningssystem för endokardit med Streptococcus och slutltligen utvärderat 
riskbedömningssystem för endokardit med Abiotrophia, Aerococcus, Gemella och 
Granulicatella. Min förhoppning är att resultaten från dessa studier kommer att 
öka förståelsen för dessa bakterier och att de på sikt kommer att leda till 
effektivare handläggning av dem i sjukvården, både vid patientmöten och inom 
klinisk mikrobiologi. 
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